Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 6/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423904 | 1.00 | KDM6B (0.40) | KDM6BPDE10AHCRTR2HCRTR1CRHR1 | |
| SCHEMBL30424397 | 0.91 | KDM6B (0.39) | KDM6BHCRTR2HCRTR1KCNH2LTC4S | |
| SCHEMBL24253942 | 0.91 | KDM6B (0.39) | KDM6BHCRTR2HCRTR1KCNH2LTC4S | |
| SCHEMBL24253944 | 0.91 | KDM6B (0.39) | KDM6BHCRTR2HCRTR1KCNH2LTC4S | |
| SCHEMBL24253622 | 0.90 | KDM6B (0.39) | KDM6BHCRTR2HCRTR1KCNH2LTC4S | |
| SCHEMBL30423911 | 0.89 | KDM6B (0.39) | KDM6BHCRTR2HCRTR1KCNH2LTC4S | |
| SCHEMBL24253939 | 0.89 | KDM6B (0.39) | KDM6BHCRTR2HCRTR1KCNH2LTC4S | |
| SCHEMBL30423987 | 0.88 | HTT (0.40) | KDM6BHCRTR2HCRTR1 | |
| SCHEMBL24253831 | 0.88 | HTT (0.40) | KDM6BHCRTR2HCRTR1 | |
| SCHEMBL24253541 | 0.80 | F10 (0.32) | KDM6BHCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | KDM6B 4108/4885PDE10A 684/4885HCRTR2 3027/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | KDM6B 4108/4885PDE10A 684/4885HCRTR2 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.